CTOs on the Move

OncoGenex

www.OncoGenex.com

 
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in ...
  • Number of Employees: 25-100
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

361md

361md - a leading healthcare IT Company, represents a complete 360 degree solution for hospitals, doctors' offices, expert physicians, diagnostic labs, pharmacies, health insurance companies and other healthcare providers including nursing homes and rehab facilities.

Park Plaza Nursing Home

Pyramid HealthCare provides on-site Rehabilitation to individuals whose level of independence is threatened by physical injury or illness. Assessment and training in functional skills by licensed Physical, Occupational and Speech Therapists helps the

Medaudit Services Inc

Medaudit Services Inc is a Midland, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Focus Health

Focus Health is a Kearney, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MolecularMD

MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.